This Biotechsees shares rise from $1 to over $11 a nd there may be no end in sight...

A HIDDEN GEM IN THE MEDTECH SPACE............................................................................... [Unsubscribe]( [BioStem Technologyes, Inc. (BSEM) sees shares rise from $1 to over $9 and there may be no end in sight....]( Catalysts are piling up for this fast-growing biotech company which may be one of the biggest biotech darlings in the making. As regenerative medicine continues to find its way into the mainstream, emerging biotech company [BioStem Technologies, Inc. (OTC: BSEM)]( is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. This includes a curated suite of versatile products called Vendaje. The company has been capturing Wall Street’s attention as its share price has risen from around $1 in July of 2023 to as high as $7.00 by year-end. [This year share prices have exceeded $9!]( One of the most exciting catalysts for potential growth comes from a recent price target increase from notable research firm Zack’s Small Cap Research. It comes shortly after the company released preliminary and unaudited numbers that showed net revenue for 4Q2023 of $11.5 million, a more than 1300% increase from the year ago period! BioStem Technologies, Inc. (OTC: BSEM) was given a $9.25 price target from Zack’s Small Cap research. Today that price target is at $18.70! The firm has written that “Investors are starting to agree with our view as the stock has moved solidly higher over the past year, moving up over 140%, while the Russell 2000 was roughly flat over the same period. The company really gained momentum in the second half of 2023 as BioStem was awarded a valuable Q code for Vendaje AC by the Centers for Medicare and Medicaid Services and solidified its funding situation. Recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories.” Zack’s Small Cap Research believes that BioStem has a solid foothold in that tough to break into community and the acceptance and use of the company’s products will continue to accelerate. [Discover why there could be further upside ahead for BioStem Technologies in 2024!]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $2,000. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com [Today's Bonus Content: Jeff Bezos backs tiny biotech with $130 mil investment](